Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01561235
Other study ID # B243
Secondary ID
Status Completed
Phase N/A
First received March 13, 2012
Last updated June 20, 2012
Start date February 2008
Est. completion date July 2008

Study information

Verified date June 2012
Source University of Copenhagen
Contact n/a
Is FDA regulated No
Health authority Denmark: The Danish National Committee on Biomedical Research Ethics
Study type Interventional

Clinical Trial Summary

Dietary protein appears to be the most satiating and thermogenic macronutrient. However, how protein exerts its effect on appetite is not fully known. The effect have been suggested to be related to a higher oxidation rate of protein compared to carbohydrate and fat, and also to a greater thermogenic effect causing greater increase in core temperature. The involvement of peripheral appetite-regulating hormones has only been sparingly investigated.

The objective is to investigate the satiating effects of meals with varying content of meat-based protein and whether a dose-response effect can be found on appetite-regulating hormones and appetite ratings.

Design: 25 men will participate in the 3-way, randomized, double-blind, crossover study. The test meals is isocaloric with 30E% fat and increasing protein content at the expense of carbohydrate. Test meals are: normal protein content (NP, 14E% protein), medium-high protein content (MHP, 25E%), and high protein content(HP, 50E%). Four-hour subjective appetite ratings and blood samples will be assessed every half-hour. Subsequently, the subjects will served an ad libitum lunch.


Description:

Dietary protein appears to be the most satiating and thermogenic macronutrient (7-11). However, how protein exerts its effect on appetite is not fully known. The effect have been suggested to be related to a higher oxidation rate of protein compared to carbohydrate and fat (12), and also to a greater thermogenic effect causing greater increase in core temperature (13). The involvement of peripheral appetite-regulating hormones has only been sparingly investigated (14). These studies have only included two preloads of different concentrations of protein. This is not an optimal design for investigating the protein dose-dependent effect as the threshold can have been reached in between the two concentrations. The effect of protein has mainly been investigated on glucagon-like peptide-1 (GLP-1), ghrelin, cholecystokinin (CCK), and generally after intake of protein below 35% of the energy content (35E%) (5;15-18). The relationship between these appetite-regulating hormones and appetite is still elusive due to contradicting results. Only one study has investigated the effect of protein preloads above 50E%. Bowen et al. (19) found that the high protein preloads could decrease the concentration of CCK and the rate of gastric emptying, which have been shown to enhance the satiating effect of food (20-22). Thus there is a need to examine the effect of protein on appetite-regulating hormones in a dose-response manner in order to detect whether there is an interaction between them and if they can be related to changes in subjective sensations of appetite and EI (14). This should be examined by comparing more than two isocaloric meals in which the protein content and one other macronutrient should vary whereas the third macronutrient should be kept fixed.

Thus, the objective of this study is to investigate the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible dose-response effect of protein is investigated on a number of appetite-regulating hormones/peptides, together with changes in ad libitum energy intake.

Design: 25 men will participate in the 3-way, randomized, double-blind, crossover study. The test meals is isocaloric with 30E% fat and increasing protein content at the expense of carbohydrate. Test meals are: normal protein content (NP, 14E% protein), medium-high protein content (MHP, 25E%), and high protein content(HP, 50E%). Four-hour subjective appetite ratings and blood samples will be assessed every half-hour. Subsequently, the subjects will served an ad libitum lunch.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy,

- BMI: 18.5-40 kg/m2,

- Weight stable (within +/- 3 kg) two months prior to study inclusion,

- Non-smoking,

- Nonathletic,

Exclusion Criteria:

- BMI > 40 kg/m2,

- Change in smoking status,

- Daily or frequent use of medication,

- Suffering from metabolic diseases,

- Suffering from psychiatric diseases,

- Suffering from any other clinical condition, which would make the subject unfit to participate in the study,

- Blood pressure was above 150/90 mmHg,

- Hemoglobin < 8 mmol/l.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
Dose-reponse effect of protein on appetite and appetite-regulating hormones
3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.

Locations

Country Name City State
Denmark Department of human Nutrition Frederiksberg

Sponsors (1)

Lead Sponsor Collaborator
University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute 4-h changes from baseline in the postprandial concentration of GLP-1 Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes.
Blood samples are analyzed for GLP-1. Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed.
Measured on 3 seperate test days in a crossover design. Each test day was seperated by >4 weeks. On each test day GLP-1 was measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake No
Secondary Acute 4-h changes from baseline in subjective appetite sensations using visual analogue scales Assessment of subjective appetite sensations (visual analogue scales (VAS)) at time 0 (baseline - prior to the test meal) and at time 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake.
Measured subjective appetite sensations of hunger, satiety, prospective consumption, fullness, composite appetite score and sensory desires to something sweet, salty, rich in fat, or meat/fish.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed.
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day appetite sensations were measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. No
Secondary Acute 4-h changes from baseline in the postprandial concentration of appetite regulating hormones/peptides Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes.
Blood samples are or will be analyzed for glucagon, pancreatic polypeptide (PP), glucose-dependent insulinotropic polypeptide (GIP), peptid YY (PYY), ghrelin, CCK, amylin and apolipoprotein-IV.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed.
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. No
Secondary Acute 4-h changes from baseline in the postprandial concentration of glucose Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes.
Blood samples was analyzed for glucose.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes post intake. No
Secondary Acute 4-h changes from baseline in the postprandial concentration of insulin Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes.
Blood samples was analyzed for insulin.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 15, 30, 45, 60, 90, 120, 150, 180, 240 minutes post intake. No
Secondary Acute 4-h changes from baseline in the postprandial concentrations of lipids Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes.
Blood samples were analyzed for triglycerides, free fatty acids (FFA), total cholesterol, HDL-cholesterol.
The concentration of low density lipoprotein (LDL) cholesterol will be estimated as described by Friedwald et al.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. No
Secondary Acute 4-h changes from baseline in the body temperature Body temperature measurement were assessed at time 0, 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake.
Temperature was measured in the participants' ears (ThermoScan 6022, Braun GmbH, Kronberg, Germany).
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day temperature was measured prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 210, 240 minutes post intake. No
Secondary Rate of gastric emptying (4-h change from baseline in postprandial concentration of paracetamol) The subjects drank 500 mg paracetamol desolved in 100 ml water together with the test meal.
Blood samples were taken prior to the test meal (baseline). After initiation of the test meal blood samples were collected at time 30, 60, 90, 120, 150, 180, 240 minutes.
Blood samples was analyzed for concentration of paracetamol.
Data are planned to be statistically analyzed as repeated measurements in mixed linear models. Peak and time to peak will also be analyzed.
Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day blood samples were collected prior to the test meal (time 0) and 30, 60, 90, 120, 150, 180, 240 minutes post intake. No
Secondary Rating of the organoleptic quality of the test meals After completion of the meal the subjects rated the organoleptic quality of the meal by visual analogue scales (VAS) in regard to appearance, smell, taste, after-taste, and general palatability of the meal. Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the test meal (approximately) time 15 minutes post intake) subjects rated the test meals No
Secondary Rating of the organoleptic quality of the ad libitum meal After completion of the meal the subjects rated the organoleptic quality of the ad libitum meal by visual analogue scales (VAS) in regard to appearance, smell, taste, after-taste, and general palatability of the meal. Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the ad libitum meal subjects rated the meal No
Secondary Subjective appetite sensations (visual analogue scales) after ad libitum meal After completion of the meal the subjects rated the subjective appetite sensations by visual analogue scales (VAS) in regard to sensation of hunger, satiety, prospective consumption, fullness, composite appetite score and sensory desires to eat something sweet, salty, rich in fat, or meat/fish. Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. On each test day after completion of the ad libitum meal subjects rated their subjective sensation of appetite (approximately 4.5-h post intake of the test meal) No
Secondary ad libitum energy intake (EI) 240 min after each test meal an ad libitum meal was served, and the total energy intake was recorded Measured on 3 seperate test days in a crossover design. Each test seperated by >4 weeks. EI was measured 240 min after intake of the test meal No
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2